Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Scope of consolidation

v3.22.1
Scope of consolidation
12 Months Ended
Dec. 31, 2021
Disclosure of significant investments in subsidiaries and associates Abstract  
Scope of consolidation

4. Scope of consolidation

Stevanato Group S.p.A. is the parent company of the Group and it holds, directly and indirectly, interests in the Group’s main operating companies. The Group’s scope of consolidation at December 31, 2021 and 2020 is as follows:

Subsidiaries and associate

The consolidated financial statement of the Group includes the following list of company directly or indirectly controlled:

 

 

 

 

 

 

 

 

 

 

 

% equity interest

Name

 

Segment

 

Description

 

Country of incorporation

 

Type of control

 

2021

 

2020

Nuova Ompi S.r.l.

 

Biopharmaceutical

 

Production of drug containment systems and development of integrated solutions for the pharmaceutical industry

 

Italy

 

Direct

 

100%

 

100%

Spami S.r.l.

 

Engineering

 

Production plant and machinery

 

Italy

 

Direct

 

100%

 

100%

Stevanato Group International a.s.

 

Holding

 

Service/Subholding company

 

Slovakia

 

Direct

 

100%

 

100%

Medical Glass a.s.

 

Biopharmaceutical

 

Production of drug containment systems

 

Slovakia

 

Indirect

 

99.74%

 

99.74%

Stevanato Group N.A. S. de RL de CV

 

Biopharmaceutical

 

Service company

 

Mexico

 

Indirect

 

100%

 

100%

Ompi N.A. S. de RL de CV

 

Biopharmaceutical

 

Production of drug containment systems

 

Mexico

 

Direct
Indirect

 

30.76%
69.24%

 

30.76%
69.24%

Ompi of America inc.

 

Biopharmaceutical

 

Sale of drug containment systems and analytical services

 

USA

 

Indirect

 

100%

 

100%

Ompi do Brasil I. e C. de
Em. Far. Ltda

 

Biopharmaceutical

 

Production of drug containment systems

 

Brazil

 

Direct
Indirect

 

79%
21%

 

79%
21%

Ompi Pharm. Packing Techn. Co. Ltd

 

Biopharmaceutical

 

Production of drug containment systems

 

China

 

Indirect

 

100%

 

100%

Innoscan A/S

 

Engineering

 

Production plant and machinery

 

Denmark

 

Indirect

 

100%

 

100%

SVM Automatik A/S

 

Engineering

 

Production plant and machinery

 

Denmark

 

Indirect

 

100%

 

65% *

Medirio SA

 

Biopharmaceutical

 

Research and development

 

Switzerland

 

Indirect

 

100%

 

100%

Balda Medical Gmbh

 

Biopharmaceutical

 

Production of in-vitro diagnostic solutions

 

Germany

 

Direct

 

100%

 

100%

Balda C. Brewer Inc.

 

Biopharmaceutical

 

Production of in-vitro diagnostic solutions

 

USA

 

Indirect

 

100%

 

100%

Balda Precision Inc.

 

Biopharmaceutical

 

Production metal components

 

USA

 

Indirect

 

100%

 

100%

Ompi of Japan Co., Ltd.

 

Biopharmaceutical

 

Sale of drug containment systems

 

Japan

 

Direct

 

51%

 

51%

Swissfillon AG

 

Biopharmaceutical

 

Sterile filling services company

 

Switzerland

 

Associate

 

0%

 

26.94%

 

* Not included in minority interests as there is a put and call option for full acquisition (the minority interests would have amounted to 35%).

Non-controlling interests

The non-controlling interests as at December 31, 2021 and the net profit attributable to non-controlling interests for the years ended December 31, 2020 and 2021 relate to Ompi of Japan Co., Ltd. and Medical Glass a.s.. For further details refer to Note 37.